Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab plus standard-of-care vs standard-of-care in HER2-positive biliary tract cancer
2023-508219-21-00Phase 3Authorised
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of zanidatamab zovodotin in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC) and 1 more (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Progression-free survival in IHC 3+ subgroup. Planned start Aug 2024; status: authorised.
02
Drugs
zanidatamab zovodotin
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2023-508219-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508219-21-00.